LUCAR-G79 T cells not checked

Nanjing Legend Biotech Co.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Prior to infusion of the LUCAR-G79 T cells, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.”In the company’s words, NCT07049081 on ClinicalTrials.gov
Tested for
Relapsed/Refractory Autoimmune Diseases
Main trialPhase 1
“This is a prospective, single-arm, open-label and dose-escalation Investigator Initialed study to evaluate LUCAR-G79 in adult subjects with relapsed/refractory autoimmune diseases.”In the company’s words, NCT07049081 on ClinicalTrials.gov

Other drugs for Relapsed/Refractory Autoimmune Diseases

All 403 drugs for Relapsed/Refractory Autoimmune Diseases

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Terminated 20 Mar 2026 A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow LUCAR-G79 T cells

Following is part of Solo: you see every change to LUCAR-G79 T cells the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in